Guillermo Izquierdo Ayuso

Early beginning of alemtuzumab: Changing the multiple sclerosis treatment paradigm. Interim analysis of the LEMVIDA study

José Meca-Lallana, José C. Álvarez‐Cermeño, Bonaventura Casanova Estruch, Guillermo Izquierdo Ayuso et autres

LEMVIDA is a real-world prospective study of 3-year follow-up on quality of life of patients with multiple sclerosis (MS) receiving alemtuzumab in Spain. This is an interim analysis evaluating the baseline characteristics of patients who started alemtuzumab between October 2016-September 2018. For …

es (code pays fourni par la source)

Incidence and prevalence of multiple sclerosis in China and other Asian countries

Guoxun Zhang, A. Carrillo-Vico, W.T. Zhang, Shuaishuai Gao et autres

The prevalence of multiple sclerosis (MS) in Asian countries is thought to be lower than in Western countries, with Asian populations presenting 80% less risk of MS than white populations. Incidence and prevalence rates in Asian countries are therefore not well defined …

es (code pays fourni par la source)

Inicio temprano de alemtuzumab: cambio en el paradigma de tratamiento en esclerosis múltiple. Análisis intermedio del estudio LEMVIDA

José Meca-Lallana, José C. Álvarez‐Cermeño, Bonaventura Casanova Estruch, Guillermo Izquierdo Ayuso et autres

LEMVIDA es un estudio de práctica clínica, prospectivo, de tres años de seguimiento sobre calidad de vida en pacientes con esclerosis múltiple (EM) tratados con alemtuzumab en España. Análisis intermedio de las características basales de los pacientes que iniciaron alemtuzumab entre octubre …

es (code pays fourni par la source)

Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry

Rachel Kenney, Mengling Liu, Sachi Patil, Raed Alroughani et autres

us, kw, cz, gb, tr, au, cu, it, es, be (code pays fourni par la source)

Comparative effectiveness of natalizumab and fingolimod in subgroups of patients with relapsing-remitting multiple sclerosis from three international cohorts (2943)

Sifat Sharmin, Mathilde Lefort, Johanna Balslev Andersen, Emmanuelle Leray et autres

To compare the relative treatment effects of natalizumab and fingolimod in subgroups with relapsing-remitting multiple sclerosis (RRMS).

us, au, fr, dk, cz, kw, cu, tr, it, ca, lb, gb, hu, mq (code pays fourni par la source)

Real-world Experience with Cladribine Tablets in the MSBase Registry (2942)

Helmut Butzkueven, Timothy Spelman, Suzanne Hodgkinson, Tomáš Kalinčík et autres

We analysed the cladribine treatment experience in the MSBase registry. We described baseline characteristics, treatment pathways, and relapse and discontinuation outcomes in patients with ≥6 months follow-up data from cladribine initiation.

us, au, se, es, fr, ca, gb, be (code pays fourni par la source)

Association of Latitude and Exposure to Ultraviolet B Radiation with Severity of Multiple Sclerosis (2554)

Marianna Vitková, Ibrahima Diouf, Charles B. Malpas, Dana Horáková et autres

The aim of this study was to investigate the association between latitude of residence, ultraviolet B radiation exposure (UVB) and the severity of multiple sclerosis (MS).

sk, au, cz, it, tr, cu, es, ir, kw, fr, ca, lb, nl, gb, be, pt, ie, us, ar, in, br (code pays fourni par la source)

Disability Accrual in Primary Progressive & Secondary Progressive Multiple Sclerosis (2901)

Sam Harding-Forrester, Izanne Roos, Sifat Sharmin, Ibrahima Diouf et autres

We compared disability accrual in primary and secondary progressive multiple sclerosis (PPMS, SPMS) in the international MSBase cohort, using multivariable survival models, and applying objective diagnostic criteria for SPMS.

au, cz, it, cu, es, ca, fr, us, nl, tr, kw, be, lb, br, gb, ir, ar, Égypte (code pays fourni par la source)

Variability of the Response to Immunotherapy Among Sub-groups of Patients With Multiple Sclerosis (4107)

Ibrahima Diouf, Charles B. Malpas, Dana Horáková, Eva Havrdová et autres

To assess whether patients’ response to disease modifying therapies (DMT) in multiple sclerosis (MS) varies by disease activity (annualised relapse rate, presence of new MRI lesions), disability, age, MS duration or disease phenotype.

au, cz, it, ir, tr, cu, es, Égypte, kw, fr, ca, lb, be, gb, ie, ar, dk, nl, in, us, br, hu (code pays fourni par la source)

Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial

Jacqueline Palace, Dean M. Wingerchuk, Kazuo Fujihara, Achim Berthele et autres

BACKGROUND: Antibodies to the aquaporin-4 (AQP4) water channel in neuromyelitis optica spectrum disorder (NMOSD) are reported to trigger the complement cascade, which is implicated in astrocyte damage and subsequent neuronal injury. The PREVENT study demonstrated that the terminal complement inhibitor eculizumab reduces …

gb, us, jp, de, es, kr, tr, ru, my, tw (code pays fourni par la source)

Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial

Bruce Cree, Gary Cutter, Jerry S. Wolinsky, Mark S. Freedman et autres

us, ca, it, de, ch, fr (code pays fourni par la source)

Incidencia y prevalencia de la esclerosis múltiple en China y países asiáticos

Guoxun Zhang, Antonio Carrillo‐Vico, Wenting Zhang, Shuaishuai Gao et autres

La prevalencia de la esclerosis múltiple (EM) en los países asiáticos se considera que es más baja que en los países occidentales, las poblaciones asiáticas tienen un 80% menos de riesgo de EM que las caucásicas. No se conocen bien las cifras …

es (code pays fourni par la source)